News
Lilly's Mounjaro shows its cardio benefits in Trulicity head-to-head trial
A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label expansions to reduce the risk of cardiovascular issues. | Eli Lilly has presented phase 3 results showing its Mounjaro measures up to the company’s GLP-1 Trulicity in reducing cardiovascular risks in patients with Type 2 diabetes and heart disease.
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...
Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...
Shares of Eli Lilly & Co. erased gains to trade down nearly 1% after White House press secretary Karoline Leavitt said the company was among 17 drugmakers that will be receiving letters from President ...
Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's ...
Eli Lilly drug Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the ...
We recently published 12 Stocks Jim Cramer Recently Discussed As He Commented On A “Sea Of Green”. Eli Lilly and Company ...
Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback